Novo NVO recently entered a new chapter by adopting "Novo" as its day-to-day name, as it seeks to sharpen its focus and competitiveness amid slowing growth and intensifying market competition. The move comes as the stock faces growing investor concerns over its outlook, with shares declining about 5% over the past week and Morgan Stanley's downgrade of the stock to "Underweight" from "Equal-weight," adding fresh pressure. Morgan Stanley retained its $40 (DKK 250) price target but raised concerns that Novo's valuation does not fully reflect muted medium-term growth and the longer-term risk from the semaglutide patent cliff.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。